Crinetics Pharmaceuticals (NASDAQ: CRNX) presented results from its Phase 2 trial of atumelnant for congenital adrenal hyperplasia at the Endocrine ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE